Celcuity Inc. - Common Stock (CELC)

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients.

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Celcuity (CELC) reported Q2 2025 results with a wider-than-expected EPS loss but revenue in line. Clinical progress in breast cancer trials drives investor optimism despite financial misses.

The trading volume of these stocks is deviating from the norm in today's session.

Discover the stocks with unexpected trading volume in today's session on the US markets.

Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected in late 2025.

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.